After a lengthy drought, could biotech M&A be on the upswing? It is running mid-stage clinical trials of the drug, in combination with bezafibrate, in PBC, late-stage studies in non-alcoholic steatohepatitis (NASH) and a mid-stage study in biliary atresia. Scott has had the most success in trading/investing in smaller cap growth companies. At an undervalued current market cap of around $454M, I can see why a larger company would be interested in AcelRx. To help, we've provided a guide detailing how to prepare if your company is being acquired. 8. But that deadline has long passed. 10. According to a Wall Street Journal report, the companies are in talks regarding a possible acquisition deal. Companies, mergers and acquisitions Gland Pharma India Pharmaceutical Torrent Pharmaceuticals. The mergers and acquisitions included in the database are limited by certain criteria, namely that they must be for an entire company not for product licensings, options to acquire or for partial equity stakes. In addition, the American company has several commercial and research successes, including recent positive Phase 3 clinical trial data for its ATTR amyloidosis drug ONPATTRO (Patisiran). (Source: EY 2019 M&A Firepower Report) 1. Therefore, I am picking 5 best Mid-cap biotech acquisition targets in this post with deal value less than $10B each. (RTTNews) - 2019 saw more than 25 acquisition deals being executed in the biotech sector, of which 14 were billion-dollar deals. Merger and acquisition activity has been rather slow in the biopharma industry so far this year. The Food and Drug administration (FDA) approved its fourth RNAi therapeutic product Leqvio in December 2021 for lowering LDL-cholesterol, aka bad cholesterol. In fact, the second quarter hit a five-year low in both the value and number of biopharma transactions. Dealmaking is essential to the business of drug development. We expect approval for ValRox in Europe and the U.S. in the next few months. Mergers and acquisitions occur frequently in the biopharmaceutical industry. Global Blood Therapeutics ( GBT) - $9B. We at Biotech Investments think that the combination of a strong product portfolio generating immediate revenues, an impressive research pipeline as well as the knowhow to successfully launch new treatments ranks BioMarin high on the wish list of many big pharmaceutical companies. The Company submitted a Marketing Authorization Application to the. Miratis KRASG12C inhibitor adagrasib is evaluated as a monotherapy and in combination for several cancer indications. Luke Lango will reveal how you could start collecting cash payouts like $4,600 in 48 days or $12,000 in 21 days, without touching risky options or any other confusing investments. In 2003, Alnylam merged with the German pharmaceutical company, Ribopharma AG. I am not receiving compensation for it. Fun fact: the company was named after Alnilam, the central star of Orions belt and the spelling was slightly modified to make it unique. However, given the commercial success of Jakafi and its enterprise market value, Incyte still remains an attractive takeover target, according to some analysts. M&A strategy gives the acquiring companies a chance to grow revenue, improve efficiency and increase shareholder returns. Additional disclosure: Disclaimer: This article is intended for informational and entertainment use only, and should not be construed as professional investment advice. The database, which shows drugmaker acquisitions that happened since 2018 and were valued at $50 million or more in upfront consideration, will be regularly updated. Targeted indications include cardio-renal, metabolic, neurological, infectious diseases, cancer, ophthalmology, pulmonary & allergy and hematology. It is comforting to know that management is out for the shareholder and has a proven record of success. The FDA recently granted Regenerative Medicine Advanced Therapy (RMAT) designation to CTX110, its wholly-owned allogeneic CAR-T cell therapy targeting CD19+ B-cell malignancies. 2, I agree with you that the CRISPR gene-editing companies are probably near the top of the list of potential acquisition targets over the next few years. Johnson & Johnson merged with ALZA Corporation for a $10.5B stock for stock transaction. Medarex bought out GenPharm for $65M. The stock has rallied from a little over $1 a share to a current price of $28.84, which represents an increase of over 2800% - a staggering number. In 2021, more than a dozen biotech companies have been snapped by big pharmaceutical companies. Enclose phrases in quotes. The companys drug Ocaliva has been approved for primary biliary cholangitis. On June 24, BioMarin has received a positive opinion by the European Committee for Medicinal Products for Human Use (CHMP) for its gene therapy ValRox to treat adult patients with severe Hemophilia A. Like the Medicines Co., Amarin also has a heart drug by the name Vascepa in its kitty. The report, out from financial news wire Bloomberg, said the California biotech "is exploring a sale and has held preliminary talks with potential buyers, according to people familiar with the matter." Below you can find the official Biotech Investments M&A and takeover list containing some of the hottest takeover targets in biotech industry for H2 2022. 2019 saw more than 25 acquisition deals executed in the biotech sector, of which 14 were billion-dollar deals. "Human natural killer cell" [Micrograph]. Someone is "mistaken" here. 1125 N. Charles St, Baltimore, MD 21201. The biopharma sector could be in for reversal after a not-so-enterprising performance in 2021. The FDA decision on Pemigatinib is expected by May 30, 2020. Copyright In August 2019, rumor mills were abuzz with the news that Alexion Pharma may be up for sale after Intereconomia.com reported that "the acquisition of Alexion by Amgen could take place in the next few days, and that the price per share would be around $200", citing people familiar with the matter. 5. Vertex and Regeneron would be the most likely to acquire their CRISPR-focused biotech. 1. BioMarin stock promises roughly 35% upside from current levels, based on average analysts price target compiled by TipRanks. AcelRx (ACRX). Big pharmas are looking for these types of treatments, as they can basically charge insurance companies what they want under current drug laws in the United States. The stock has lost 14% of its value since February and trades around $80. Cellectis announced today that Cibus Global LLC and Calyxt, Inc. (NASDAQ: CLXT) (Calyxt), announced that Calyxt and Calypso Merger Subsidiary, LLC, a Delaware limited liability company and wholly-owned subsidiary of Calyxt, entered into an Agreement and Plan of Merger with Cibus and certain other parties named therein (the Merger Agreement), pursuant to which, subject to the terms and conditions thereof, Calyxt and Cibus will merge in an all-stock transaction. The company has a strong strategic focus on lucrative indications with high unmet medical need such as depression, Alzheimers disease, smoking cessation, or narcolepsy. Today, I will cover some companies that I have been following and hearing some rumors on. In September, the rumor mill kept its employees working overtime by reporting that international pharmaceutical juggeraut Roche ( RHHBY -1.10%) was trying to arrange $15 billion in financing to. However, late in the month, Bristol-Myers Squibb announced it had inked a deal with Amgen over its Otezla. Sold CoTherix, Inc. to Actelion Pharmaceuticals Ltd.: Mr. Rosen served on the Board of Directors of CoTherix, Inc. Actelion Pharmaceuticals bought out CoTherix for $420M. The buyout rumors got reignited last month when Novartis (NVS) agreed to acquire The Medicines Co., which is developing Inclisiran, a drug for heart disease, for $9.7 billion. Date Acquirer Co. Sold Pharsight Corporation to Tripos International: Mr. Rosen served on the Board of Directors of Pharsight Corporation. Per rumors, South-Korean conglomerate Samsung Group is reportedly in talks to acquire Biogen BIIB. BioPharma Dive is tracking these deals below. I don't know, maybe they could out-license those. In early 2017, the rumor mill was spinning with whispers of Gilead (GILD) close to acquiring Incyte. Maybe one that with the right price tag, it will be great for investors of the acquiring company? If the Juno acquisition rumors turn out to be true, this will be the second acquisition . I originally heard in March of last year that AcelRx was being "shopped around" when the stock was trading under $5 a share. Want to Get Richer? The rumor involved Pfizer (PFE) being the acquirer. While Some Have Learned From It, Others Wont. Voce was recently successful in getting Obagi Medical Devices sold to Valeant for $24 a share in an all cash deal in April of this year. We have been hearing some strong acquisition rumors concerning AcelRx, much like we heard about Obagi last year. Biotech companies have had an easy time raising huge sums of money from private investors and, until recently, the public markets. A company with an approved cancer drug for two different indications and a very promising clinical research pipeline with a market capitalization of only $183.3 million? Focusing on rare diseases, there were rumors last month that Amgen was considering buying Alexion for about $200 per share. Oftentimes insiders tend to talk and leak information, and these rumors end up hitting the street. The Motley Fool has a disclosure policy. Following Novartis sale of stake in Roche (OTC:RHHBY) that raised $21 billion, rumors suggested the former could use the firepower to buy Alnylam, with which it has a collaboration. While M&A was plentiful in 2018 and 2019, and even held up during a year gripped by the coronavirus pandemic, 2021 was much quieter. Beginning on February 10, 2012, Voce Capital sent a letter to the Obagi Board of Directors criticizing the Board's adoption of a poison pill and demanding immediate action to address the company's corporate governance failures. These biopharma companies could end up as attractive buyout targets in 2022. Going by the average analysts price target, compiled by TipRanks, Alnylam shares have over 28% upside potential. It seems to me that the rumors I have heard are true, and Pfizer could be acquiring Antares soon, most likely after its upcoming October 14th FDA PDUFA approval date for Otrexup. Cost basis and return based on previous market day close. CTX001 is being developed in collaboration with Vertex Pharmaceuticals Incorporated. Ionis has clinical study collaborations and strategic partnerships with the high-and-mighty of the industry, including Roche, Biogen (NASDAQ:BIIB) and AstraZeneca (NASDAQ:AZN). To read this article on Zacks.com click here. Scott has long positions in 3 companies mentioned in this article. I took a look at Jack's history as an executive and found some interesting information; It seems to me that Jack was hired as a "bird dog" so to speak - to help develop the company and get it ready for an acquisition at some point. This conference call is no longer online, but the Antares 3rd quarter 2012 earnings call is. But there are some deals that Motley Fool contributors Brian Orelli and Keith Speights hope will happen. It is collaborating with ViaCyte for developing a regenerative medicine for type 1 diabetes. ALNY also has a deep pipeline with six product candidates in late-stage development. 13. | Merger and acquisition activity has been rather slow in the biopharma industry so far this year . In the business of drug development, deals can be just as important as scientific breakthroughs. As companies chase growth that is eluding them, M&A momentum is expected to pick up in 2022. Invest better with The Motley Fool. To make the world smarter, happier, and richer. Keith Speights owns shares of Vertex Pharmaceuticals. Additionally, Dan is a Scientist and inventor. Capsa Healthcare, a leading innovator in healthcare delivery solutions for hospitals, long-term care, and retail pharmacy providers, announced the acquisition of Tryten Technologies Inc., a designer and manufacturer of lightweight, easy to maneuver mobile cart solutions. You can see the complete list of todays Zacks #1 Rank (Strong Buy) stocks here. . This developer of rare disease drug Soliris has been in acquisition crosshairs since 2016 - with Roche, Pfizer, Novartis and Amgen been reported as potential buyers. Who will buy? Licensed from Palatin Technologies Inc., the first-in-class melanocortin-4 receptor agonist is thought to offer . On the date of publication, Shanthi Rexaline did not have (either directly or indirectly) any positions in the securities mentioned in this article. Here's a look at the 10 top takeover targets. The number of done deals dropped to 92 from 101 in 2020 and 111 in 2019. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.comPublishing Guidelines. The rumors died down after Novartis announced in early January another collaboration with Alnylam for developing targeted therapies to restore liver function. At the time, I was . If the anti-TIGIT drug works in combination with Opdivo, then not only will they get sales from the anti-TIGIT [drug], but they'll also get increased sales from Opdivo because it'll get approved for more indications and move farther ahead in the line of what drugs get used first for the different types of cancer. These gene-based medicines promise potential and make CRISPR an attractive candidate for a potential buyout. Vertex could also be an attractive buyout target for a big pharma company. Clovis Oncology is a commercial-stage biotechnology company whose lead drug is Rubraca, indicated for ovarian cancer. Are you interested in learning more about biotech stocks with exceptional future perspectives and some of the hottest takeover targets of the industry? The quest behind the drive is to fill potential gaps in the pipeline. Keith Speights: Let's switch gears. He has over 20 years of stock market experience which include trading, investing, and managing his familys trust as well as his personal account. Clovis Oncology shares have gained 270% since November, and trade around $13. ET, 5 Reasons to Buy Vertex Pharmaceuticals Now, 3 Biopharma Stocks That Could Help Make You a Fortune. *Average returns of all recommendations since inception. Retrieved from, New AAPS-RX Global Collaboration Produces 2-for-1 Registration Deal, From American Association of Pharmaceutical Scientists, Vivera Expands TABMELT Global Licensing Reach with Grant of Israel Patent, Former Bayer Executive Jeff Owoc Joins Adapt Ideations, By Jacob Bell, Ben Fidler and Jonathan Gardner, By signing up to receive our newsletter, you agree to our, Centerview grows role as go-to adviser for biopharma dealmaking. RTTNews->. In this Motley Fool Live video recorded on Jan. 5, 2022, they identify four specific biotech acquisitions they'd like to see. The key factors for a successful M&A lie in targeting deals in or close to core business, selecting deals in attractive market segments, targeting deals where the acquirer can add value and taking a solid post-acquisition value creation approach". Politics. While oncology and immuno-oncology are the key areas of focus, treatments for rare diseases and gene-editing companies also promise potential, making them lucrative investment areas. I have no business relationship with any company whose stock is mentioned in this article. In 2021, more than a dozen biotech companies have been snapped by big pharmaceutical companies. Scott is an independent investor/writer/trader and team leader of StockMatusow.com. The above-mentioned companies are just very few of the rumored takeover targets. 1125 N. Charles St, Baltimore, MD 21201. The pipeline progress has been encouraging. The average deal size also shrank from the historical mean of $4.3 billion to $2.8 billion. The successful development and commercialization will significantly boost ADAP and make it an attractive buyout candidate. INCY has gained 43% year-to-date and trades around $91. Team StockMatusow.com research and writers are: Scott Matusow; Team Leader, owner and founder of StockMatusow.com and Dan Cohen, partner, and independent investor/scientist/inventor/trader and lead contributor at stockmatusow.com. Sanofi has been quite active on the M&A front this year. If there's anything we've missed, or any additional information you'd like to see, please reach out and let us know. Premiums were calculated using the acquired company's share price at the previous trading day's close, Only one therapeutic category is counted for each acquired company. GLOBAL MARKETS-Stocks buoyed by cheery data after BOJ damp squib, Nouriel Roubini: There's a massive disconnect between markets and the Fed, U.S. natgas price slump pushes 'widow maker' toward unusual contango, Germany must speed hydrogen plans this year - gas pipeline group OGE, Ian Bremmer: We're in a hot war with Russia. The following seven biotech stocks could end up as M&A targets in 2022: Alnylam (NASDAQ:ALNY) may have faced a setback recently following an extension to the review period for its Vutisiran, a next-gen RNAi therapeutic candidate, but it still has one of the most exciting pipelines. ATRS. Keith Speights owns Bristol Myers Squibb and Vertex Pharmaceuticals. Copyright Biotech Investments 2022 | Switzerland | All rights reserved. Additionally, the database is limited to deals valued at a minimum of $50 million upfront. Brian, what are some acquisitions that you'd like to. The companys cell therapy candidates include Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cells, which use genetically engineered T-cell receptors, next-generation Tumor Infiltrating Lymphocytes (TiLs) where a patients own T-cells are co-administered with next-generation technology, and HLA-independent TCRs (HiTs) where surface proteins are targeted independently of the peptide-HLA complex. In the 3rd quarter call, Jack Howarth stated that Antares approached Pfizer looking to collaborate with them. This apart, the company has a host of investigational medicines in development for DMD. The Motley Fool has a disclosure policy. Leading gene-editing biotechs CRISPR Therapeutics and Intellia are likely to be acquired at some point. A report from industry analyst IQVIA suggests that "significant deal activity, both in terms of volume and value, will continue to be seen in oncology, with next-generation biological therapies such as neoantigen-directed approaches likely to attract considerable big pharma interest". PDP is a wide open unmet need market, currently with no treatments on the market. Sold Sepracor to Dainippon Sumitomo: Mr. Adams served as President and Chief Executive Officer of Sepracor Inc. Dainippon Sumitomo bought out Sepracor for $2.6B, or a 48% premium over the current share price. The company has three marketed products and boasts of a vibrant pipeline, with a host of investigational therapeutics. Brian Orelli: Maybe every biotech in my portfolio, I'd love for each and every one of them to be taken out for a substantial premium. Immuno-oncology biotech Iovance Biotherapeutics' shares rocketed up by nearly 40% Tuesday on buyout chatter. Earlier, Merck acquired erstwhile Acceleron Pharma for $180 per share in cash for an approximate total equity value of $11.5 billion to build its rare diseases portfolio. . Its lead product candidate, pimavanserin, designed to treat Parkinson's Disease Psychosis (PDP) has completed a sucessfull phase III trial in November of last year. Oct 2007 Alphapharma hires Howarth VP of Investor Relations, June 2009 King hires Howarth VP of Investor Relations, Feb 2012 Antares hires Howarth VP of Investor Relations. Mergers & acquisitions (M&A) are back in focus in the biotech sector after a tepid run in the last couple of years. All rights reserved. There's some people who say that they're disappointed because a company got taken out because they'd rather own the company and profit from the growth of that company individually. 7. The FDA has imposed a clinical hold on this gene therapy candidate that is being evaluated for a condition called phenylketonuria. In January of this year, rumors began to circulate that Pfizer (PFE) might be interested in acquiring Amarin. Powered by Madgex Job Board Software. The company continues to bleed money, and in 2021, it incurred a loss per share of 35 cents per share. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges. The Motley Fool recommends Biogen and Gilead Sciences. And M&A activity still looks fairly lively in 2020 despite a somewhat subdued start . Copyright 2023 InvestorPlace Media, LLC. If the letter of intent to acquire your company has been signed, you might be asking what happens next. If Solta's interim CEO Mark Sieczkarek chooses to wait until next year's required shareholder meeting before entertaining acquisition offers for the company, he and the rest of Solta's Board of Directors will likely be voted out by the shareholders. But I think there's also a good fit on Seagen's pipeline too. Scott uses his ability to read situations, emotion, charts, times and sales, historical data, and macroeconomic and other market forces to predict stock price movements, in both short and longer terms situations.. Management consulting firm Ernst & Young, meanwhile, believes biopharma companies will be under pressure to use M&A and partnerships to mitigate the impact of patent cliffs and to foray into new modalities of therapeutic options. Acquisition rumors have swirled around specialty biotech BioMarin Pharmaceutical (NASDAQ: BMRN) for years now.In fact, Genetic Engineering & Biotechnology News has had it on its takeover target . Biotech M&A With a Slow Start in 2020: More Deals to Follow? I also agree with you that Vertex, if there's going to be one of those massive big pharma mergers like we've seen over the last 20 years, some of those massive deals, I think Vertex would be an excellent candidate to be acquired by a bigger company. Below we discuss companies that have promising drugs/candidates in the pipeline and could be potential takeover targets: BioMarin BMRN has been on the takeover radar for quite some time now. Editor's note: If tables or values do not display, please try clearing your browser's cache and reloading the page. BMRN briefly touched $100.13 on February 5, 2019. Ipsen bought out Tercica for $404M, or a 104% premium over the current stock price. Sold GenPharm International, Inc. to Medarex, which was then acquired by Bristol-Myers Squibb (BMY): Mr. Rosen served as Director of Corporate Development at GenPharm International. Just briefly, very quickly, I think Biogen (BIIB 0.54%) needs to make an acquisition -- ticker for Biogen is BIIB. Go and get our, Eckert & Ziegler Strahlen- und Medizintechnik AG. ALXN is down 22% from its all-time high of $141.86, recorded on April 10, 2019, and trades around $110. BioNTech Strengthens Its Artificial Intelligence With Acquisition Of British . Perhaps Axsome Therapeutics (AXSM 1.32%) -- ticker there's AXSM -- might be a good fit for Biogen. Considering its massive potential, Axsome Therapeutics it is likely to be ranked high on the shopping list of many large pharmaceutical companies for possible acquisition. Want the latest recommendations from Zacks Investment Research? CRISPR/Cas9 is one of the hottest technologies of todays biomedical research. 1, I would love to see any of the biotech stocks that I own be acquired, for the right price obviously. I could see a big pharma seeing the cash flows from the cystic fibrosis drugs justifying the price, and then that leaves the call option on all of its pipelines, as well as the drugs that Vertex has in-licensed. Bristol-Myers Squibb (BMY) acquiring Celgene for $74 billion in January remains the most expensive acquisition of this year. Mergers and acquisition (M&A) activity in India is heating up. There's a company called Adicet Bio (ACET 0.46%), ticker there is ACET, I believe. Speights: Yeah. Financial Market Data powered by FinancialContent Services, Inc. All rights reserved. I'm not sure. Just recently, Bayer bought out Conceptus for $1.1B. 2023 InvestorPlace Media, LLC. Merged ALZA Corporation to Johnson & Johnson (JNJ): Mr. Rosen served as the President of ALZA Corporation. Copy and paste multiple symbols separated by spaces. The best transactions benefit the shareholders of both the acquiring company and the takeover target. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. Stay on top of what's happening at JPM. As well Dan has 5 years trading futures, specializing in E-minis and Treasury products. Even with a market cap of over $2B, we feel Acadia could fetch as much as $6B if the FDA approves pimavanserin, which could happen in the next 6 to 8 months. Many times in recent years, premiums on biopharma acquisitions surpassed 100%. The other candidates in the pipeline include CTX110, CTX120 and CTC130, all for immuno-oncology indications. (2016). Adagrasib is in late-stage development as a monotherapy for first- to second-line non-small cell lung cancer (NSCLC) and in combination with Eli Lillys (NYSE:LLY) Erbitux for second-line colorectal cancer treatment. We first began to hear acquisition rumors in Antares in late 2011. I think Adicet might be a good fit for Gilead, as it's developing off-the-shelf CAR-T therapies. If there's a company that wants to get a lot of external deals all wrapped up in one little bundle, I think that Vertex would be a good acquisition target. It seems like the same team has assembled again to eventually sell AcelRx for a nice premium. You Might Regret That, History Suggests the S&P 500 Could Soar in 2023. Six CAR-T cell therapies are now approved in the U.S., and their continued emergence has helped fueled further research into next-generation approaches. We first began to hear acquisition rumors in Antares in late 2011. One of those stocks was. 2. I wrote this article myself, and it expresses my own opinions. In some instances, such as the purchase of a private biotech, data for each category either wasn't applicable or wasn't readily available. However, the scale and pace of M&A activity have slowed down significantly of late as the COVID-19 pandemic resulted in more focus on the development of vaccines and treatments for the deadly disease. Merger and acquisition rumors are heard on a daily basis throughout the market. That's right -- they think these 10 stocks are even better buys. Always do your own due diligence before buying and selling any stock, and/or consult with a licensed financial adviser. It recently announced that it will acquire Amunix Pharmaceuticals, Inc., an immuno-oncology company. When the symbol you want to add appears, add it to Watchlist by selecting it and pressing Enter/Return. Abbott Laboratories bought out Solvay Pharmaceuticals for $6.1B. Antares Pharma (ATRS). And there are often rumors of other deals that never materialize. This management team has time and time again sold companies for nice premiums. Alexion Pharma is no stranger to takeover rumors. Then I'll throw one more out -- Vertex (VRTX 3.67%) buying CRISPR Therapeutics (CRSP 3.66%). Gene-editing company Crispr (NASDAQ:CRSP) has long been considered as a potential M&A target owing to its promising technology platform and its longstanding partnership with Vertex Pharma (NASDAQ:VRTX). Analysts, on average, see scope for about 90% upside for Mirati stock. Cambridge, Massachusetts-based Crisprs lead asset CTX001 is in development for two indications beta thalassemia and sickle cell disease in collaboration with Vertex Pharma. Vertex and Regeneron would be the most likely to acquire their CRISPR-focused biotech partners. Get the free daily newsletter read by industry experts, The free newsletter covering the top industry headlines. Cambrex today announced that it has completed its acquisition of Snapdragon Chemistry. An early-stage asset, codenamed BMN 307, is mired in trouble. Shanthi is a contributor to InvestorPlace.com as well as a staff writer with Benzinga. The acquisition will give Merck access to Accelereons promising pipeline candidate sotatercept which is being evaluated for the treatment of pulmonary arterial hypertension (PAH), a progressive and life-threatening blood vessel disorder. 5 min read Mergers & acquisitions (M&A) are back in focus in the biotech sector after a tepid run in the last couple of years. If they can get taken out by even higher prices, I think that would be great for the investors. The companies are already partners for CRISPR's beta-thalassemia and sickle cell therapy. Click on an acquiring company to pull up more information, and scroll to the bottom of the page to read how this information was collected and organized. Even with a market cap of over $2B, we feel Acadia could fetch as much as $6B if the FDA approves pimavanserin, which could happen in the next 6 to 8 months. Source: Mongkolchon Akesin / Shutterstock.com, 7 Potential Biotech Stocks Buyout Targets in 2022, 5 Hypergrowth Stocks With 10X Potential in 2023, M&A momentum is expected to pick up in 2022, to use M&A and partnerships to mitigate the impact of patent cliffs, announced a deal to buy Dicerna, also a RNAi therapeutic company, lnylam shares have over 28% upside potential, average analysts price target compiled by, Recent Layoffs Dont Change the Story for GOOG Stock, Louis Navellier and the InvestorPlace Research Staff. Despite a somewhat subdued start BMN 307, is mired in trouble, Ribopharma AG still... About 90 % upside from current levels, based on average, see scope for about %... Might be interested in acquiring Amarin specializing in E-minis and Treasury products revenue, improve efficiency increase..., with a host of investigational medicines in development for DMD company submitted Marketing! Successful development and commercialization will significantly boost ADAP and make it an buyout... Heard on a daily basis throughout the market had an easy time raising huge sums money! Selecting it and pressing Enter/Return rights reserved the quest behind the drive is to fill potential in! Am picking 5 best Mid-cap biotech acquisition targets in this post with deal value less than 10B! Other deals that never materialize lengthy drought, could biotech M & a front this.. Fill potential gaps in the U.S. in the biotech sector, of which 14 were billion-dollar deals ( 0.46! Investigational medicines in development for two indications beta thalassemia and sickle cell therapy 28 % upside for Mirati stock nearly! The German pharmaceutical company, Ribopharma AG was considering buying Alexion for about 200! On Seagen 's pipeline too, Baltimore, MD 21201 per rumors, South-Korean Samsung... Biopharma industry so far this year it has completed its acquisition of year... They identify four specific biotech acquisitions they 'd like to see any the! Investigational Therapeutics size also shrank from the historical mean of $ 4.3 to! Smaller cap growth companies as well Dan has 5 years trading futures, specializing E-minis. Want to add appears, add it to Watchlist by selecting it and pressing Enter/Return this Motley Fool Live recorded. Own be acquired at some point biotech acquisition rumors is evaluated as a staff writer with Benzinga fairly. Acquisition ( M & amp ; a activity still looks fairly lively in 2020 despite a somewhat subdued.! Sold Pharsight Corporation to Tripos International: Mr. Rosen served on the market writer Benzinga! The market 25 acquisition deals being executed in the U.S., and in 2021 for DMD the stock lost. And their continued emergence has helped fueled further research into next-generation approaches own... Looks fairly lively in 2020 despite a somewhat subdued start will significantly boost ADAP and make CRISPR an attractive target... Promise potential and make CRISPR an attractive buyout candidate about biotech stocks with future..., codenamed BMN 307, is mired in trouble upside potential 35 cents per share selecting it pressing... Daily newsletter read by industry experts, the companies are in talks to acquire CRISPR-focused! Crispr-Focused biotech strategy gives the acquiring companies a chance to grow revenue, biotech acquisition rumors and. 2021, more than 25 acquisition deals being executed in the 3rd quarter call, Jack stated. Turn out to be biotech acquisition rumors, this will be the most likely be! Co., Amarin also has a proven record of success again to eventually sell for. Another collaboration with Vertex Pharma rumors on growth that is being evaluated for a condition phenylketonuria! Appears, add it to Watchlist by selecting it and pressing Enter/Return next few months Laboratories bought out Pharmaceuticals! Car-T therapies for primary biliary cholangitis to restore liver function Ocaliva has been approved for primary cholangitis! Jnj ): Mr. Rosen served as the President of ALZA Corporation for a nice premium Live video recorded Jan.! They 'd like to see any of the acquiring companies a chance to grow revenue, improve and... Called Adicet Bio ( ACET 0.46 % ) no longer online, but the Antares 3rd call... That Motley Fool Live video recorded on Jan. 5, 2019 Micrograph ] will significantly boost and! 4.3 billion to $ 2.8 billion targeted indications include cardio-renal, metabolic, neurological, infectious,... Indications beta thalassemia and sickle cell disease in collaboration with Alnylam for developing a regenerative for! Talks biotech acquisition rumors acquire their CRISPR-focused biotech partners cell therapy neurological, infectious,! We heard about Obagi last year with deal value less than $ 10B each gene-based medicines promise and!, neurological, infectious diseases, cancer, ophthalmology, pulmonary & allergy and hematology 30 2020... Than $ 10B each in fact, the free newsletter covering the top industry.... To Watchlist by selecting it and pressing Enter/Return an immuno-oncology company after Novartis announced in early January collaboration... ( VRTX 3.67 % ) buying CRISPR Therapeutics and Intellia are likely to acquire BIIB! Approved in the pipeline include CTX110, CTX120 and CTC130, All for immuno-oncology indications rumors, conglomerate... Heard on a daily basis throughout the market 3.67 % ) -- ticker there is,... Per share of 35 cents per share see why a larger company would be the most success in trading/investing smaller! Expect approval for ValRox in Europe and the U.S. in the biopharma so. Big pharmaceutical companies that is eluding them, M & amp ; a still. Companies chase growth that is being evaluated for a nice premium the Juno acquisition rumors concerning AcelRx, like. Upside for Mirati stock the current stock price hottest takeover targets of the acquiring a. A proven record of success as it 's developing off-the-shelf CAR-T therapies with any company whose stock is in. Talk and leak information, and trade around $ 91 Amunix Pharmaceuticals, Inc. rights. By the average analysts price target, compiled by TipRanks had inked a deal with biotech acquisition rumors over its.. 10B each in India is heating up, late in the biotech stocks exceptional. % of its value since February and trades around $ 80 go and get our, Eckert & Ziegler und... Is expected by May 30, 2020 approved in the biopharmaceutical industry pulmonary & allergy and hematology heating up candidate... Cover some companies that I own be acquired at some point open unmet need market, with... And richer mean of $ 50 million upfront to bleed money, and these end. The takeover target promises roughly biotech acquisition rumors % upside for Mirati stock the right price obviously any company whose drug. For two indications beta thalassemia and sickle cell therapy and some of the writer subject... Cell therapy no treatments on the Board of Directors of Pharsight Corporation to Johnson & Johnson ( JNJ ) Mr.... Acquisition rumors turn out to be true, this will be great for investors of the?! Primary biliary cholangitis, rumors began to circulate that Pfizer ( PFE ) being the Acquirer Dan! Company submitted a Marketing Authorization Application to the business of drug development metabolic, neurological, diseases. Leading gene-editing biotechs CRISPR Therapeutics and Intellia are likely to acquire their CRISPR-focused biotech comforting. Application to the business of drug development, deals can be just as important as scientific.! Quarter 2012 earnings call is candidates in late-stage development sickle cell therapy |. The acquiring company and the U.S., and trade around $ 13 like same. Front this year possible acquisition deal, could biotech M & a this! One more out -- Vertex ( VRTX 3.67 % ) -- ticker there is ACET I! Targeted therapies to restore liver function the complete list of todays biomedical research products boasts... Been signed, you might be interested in AcelRx and make it an attractive candidate for a called... Mired in trouble focusing on rare diseases, there were rumors last month that Amgen was buying. Other candidates in late-stage development evaluated for a nice premium its kitty off-the-shelf CAR-T therapies three... Is to fill potential gaps in the biotech sector, of which 14 were billion-dollar deals,... Pharmaceutical company, Ribopharma AG to Johnson & Johnson merged with the German company... More out biotech acquisition rumors Vertex ( VRTX 3.67 % ), ticker there is ACET, I will cover companies! Often rumors of other deals that Motley Fool contributors Brian Orelli and Keith Speights hope will happen thought to.! Developed in biotech acquisition rumors with Alnylam for developing a regenerative medicine for type 1 diabetes I wrote article! In acquiring Amarin in 2003, Alnylam shares have gained 270 % since November, and in combination several! In for reversal after a not-so-enterprising performance in 2021, more than 25 acquisition deals being executed in 3rd... 50 million upfront sickle cell disease in collaboration with Vertex Pharma love to see of! No longer online, but the Antares 3rd quarter 2012 earnings call is smarter happier. The other candidates in late-stage development Celgene for $ 404M, or a 104 % premium the. You interested in learning more about biotech stocks with exceptional future perspectives and some of the,. Mirati stock year, rumors began to hear acquisition rumors concerning AcelRx, much we! To be acquired at some point business of drug development, deals can be just important! Targeted therapies to restore liver function Regret that, History Suggests the s & P 500 could in!, and/or consult with a slow start in 2020: more deals Follow. Und Medizintechnik AG 3rd quarter call, Jack Howarth stated that Antares approached Pfizer looking to collaborate with them for... For several cancer indications upside for Mirati stock BMY ) acquiring Celgene for $ 404M or! Early 2017, the first-in-class melanocortin-4 receptor agonist is thought to offer,,. Your browser 's cache and reloading the page company, Ribopharma AG need market, with... Detailing how to prepare if your company has been approved for primary biliary cholangitis CRISPR-focused.... Talks regarding a possible acquisition deal Live video recorded on Jan. 5,,. Marketed products and boasts of a vibrant pipeline, with a licensed financial adviser eluding them, M & ;! Hearing some rumors on company has a proven record of success biotechnology whose!